Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases

详细信息    查看全文

• 作者：Julie A. Douthwaite^a ; Donna K. Finch^b ; Tomas Mustelin^c ; Trevor C.I. Wilkinson^a ; ^{wilkinsont@medimmune.com}
• 关键词：ASM ; airway smooth muscle ; CFTR ; cystic fibrosis transmembrane conductance regulator ; COPD ; chronic obstructive pulmonary disease ; FPR ; formyl peptide receptor ; GPCR ; G protein-coupled receptor ; TRP ; transient receptor potential
• 刊名：Pharmacology & Therapeutics
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：169
• 期：Complete
• 页码：113-123
• 全文大小：983 K
• 卷排序：169

文摘

The development of recombinant antibody therapeutics continues to be a significant area of growth in the pharmaceutical industry with almost 50 approved monoclonal antibodies on the market in the US and Europe. Therapeutic drug targets such as soluble cytokines, growth factors and single transmembrane spanning receptors have been successfully targeted by recombinant monoclonal antibodies and the development of new product candidates continues. Despite this growth, however, certain classes of important disease targets have remained intractable to therapeutic antibodies due to the complexity of the target molecules. These complex target molecules include G protein-coupled receptors and ion channels which represent a large target class for therapeutic intervention with monoclonal antibodies. Although these targets have typically been addressed by small molecule approaches, the exquisite specificity of antibodies provides a significant opportunity to provide selective modulation of these important regulators of cell function. Given this opportunity, a significant effort has been applied to address the challenges of targeting these complex molecules and a number of targets are linked to the pathophysiology of respiratory diseases. In this review, we provide a summary of the importance of GPCRs and ion channels involved in respiratory disease and discuss advantages offered by antibodies as therapeutics at these targets. We highlight some recent GPCRs and ion channels linked to respiratory disease mechanisms and describe in detail recent progress made in the strategies for discovery of functional antibodies against challenging membrane protein targets such as GPCRs and ion channels.